Clinical Trial

Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore whether 4 courses of dual HER2 blockade combined with taxanes can lead to a similar prognosis with current standard treatment, which is one-year trastuzumab monotherapy combined with chemotherapy, while reducing the adverse reactions of treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-04; most recent amendment 2024-11-24.
Status change: Not Yet Recruiting → Recruiting 2024-03-13
Trial Details
NCT Number NCT05891561
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Breast Cancer
Enrollment 120 participants
Start Date 2023-11-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-27